Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| LYCALycia Therapeutics, Inc. | Bong Y. Koh / Venrock Healthcare Capital Partners III, L.P.10% Owner | $37.7M | New stake | |||
| Includes 1,944,444 shares at $18.00 IPO allocation price ($35.0M) + 101,016 shares open-market at $25.68–$26.84 (~$2.65M). Stock now $26.11: +45.1% vs $18 IPO, -0.6% vs open-mkt avg ~$26.28. IPO closed Oct 26; conversion of Series C/D preferred to common also occurred that day. | ||||||
| MSMMSC Industrial Direct Co., Inc. | Mitchell JacobsonDirector / 10% Owner | $29.0M | Added | |||
| Wtd avg $115.94 (range $115.11–$116.72) across three tranches on Oct 23. No 10b5-1 plan cited. Also gifted 8,200 shares (code G). Stock now $118.38 (+2.1% since buy). Founder-family discretionary conviction buy. | ||||||
| LRNStride, Inc. | Dylan G. Haggart / Fivespan Partners, LPDirector | $12.2M | Added | |||
| Three tranches: 59,188 shares at $79.84 (Oct 23), 4,152 at $78.47 + 90,856 at $78.44 (Oct 26). Wtd avg ~$78.98. Stock now $79.21 (+0.3% since buy). Shares held indirectly through Fivespan Partners and Fivespan Partners Fund Ltd. Post-transaction holding: 1,898,911 shares. | ||||||
| SRRKScholar Rock Holding Corp | Srinivas Akkaraju / Samsara BioCapitalDirector | $12.0M | Added | |||
| Six tranches across Oct 23 and Oct 26. Price ranges: $40.77–$41.75 (Oct 23), $41.78–$41.85 (Oct 23 second lot), $41.15–$41.93 (Oct 26). Wtd avg ~$41.45. Stock now $42.49 (+2.5% since buy). Held via Samsara BioCapital LP and Samsara Opportunity Fund LP; Akkaraju is founder/MD of Samsara, a healthcare-focused VC. | ||||||
| AIOKAI OKTO Corp. | Petros PanagiotidisChief Executive Officer / Director | $1.06M | Added | |||
| Six tranches on Oct 23. Prices ranged $5.53–$13.36, wtd avg ~$8.15. Shares held via Pani Corp (indirect). Stock now $13.42 (+64.7% since buy). CEO aggressively accumulated during an intraday swing — appears to be well-timed. | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings. 5 qualifying buys (≥ $250K, transaction type P) totalling $91.9M.
LYCA — IPO Day Buy: Venrock's $35M purchase at the $18.00 IPO price is an offering allocation (IPO committed capital), not a secondary-market buy; their additional $2.65M in post-IPO open-market purchases at $25–$27 reflects continued conviction after the stock immediately popped. Lycia Therapeutics is a newly-public clinical-stage bispecific antibody company (EGFR × LGR5 and related targets). The VC is keeping risk-on despite having already converted ~$40M+ of preferred into common at IPO.
MSM — Founder-Family Conviction: Jacobson is a founder-family 10% owner making a very large discretionary open-market purchase (~250K shares, no 10b5-1 plan cited). MSC Industrial Direct is an industrial distributor with historically resilient cash flows — this signals deep value conviction during what may be sector softness.
LRN + SRRK — Simultaneous Director Buys: Both filed Oct 27, with trade dates Oct 23–26. Stride is a K-12 digital learning company; Scholar Rock is a muscle-disease biotech focused on TGF-β biology. Different sectors, but the back-to-back large director purchases in the same EDGAR window are worth noting as a cross-sector signal of insider optimism after any mid-week softness.
AIOK — CEO Timing: The CEO's $1.1M buy at ~$8.15 avg appears prescient — AIOK has surged to $13.42 (+64.7%) as of today's quote. The wide price range ($5.53–$13.36) across six tranches suggests aggressive accumulation through a volatile session.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.